Barchart.com
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Igm Biosciences Inc (IGMS)

Igm Biosciences Inc (IGMS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.1900 -0.0800 (-6.30%) 04/16/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.1900 unch (unch) 16:02 ET
Quote Overview for Wed, Apr 16th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Day Low
1.1600
Day High
1.2802
Open 1.2600
Previous Close 1.2700 1.2700
Volume 121,300 121,300
Avg Vol 169,285 169,285
Stochastic %K 76.37% 76.37%
Weighted Alpha -74.10 -74.10
5-Day Change +0.1300 (+12.26%) +0.1300 (+12.26%)
52-Week Range 0.9200 - 22.5000 0.9200 - 22.5000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
 Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,914
  • Shares Outstanding, K 59,775
  • Annual Sales, $ 2,680 K
  • Annual Income, $ -195,800 K
  • EBIT $ -209 M
  • EBITDA $ -206 M
  • 60-Month Beta 0.58
  • Price/Sales 26.55
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 537.35% ( +223.52%)
  • Historical Volatility 79.23%
  • IV Percentile 98%
  • IV Rank 66.59%
  • IV High 782.23% on 03/14/25
  • IV Low 49.32% on 08/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 58
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 654
  • Open Int (30-Day) 930

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.26
  • Low Estimate -0.55
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +50.60%
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Get delivered to your inbox for FREE:
Sign Up.

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9200 +29.35%
on 04/09/25
Period Open: 1.2350
1.3100 -9.16%
on 04/15/25
-0.0450 (-3.64%)
since 03/14/25
3-Month
0.9200 +29.35%
on 04/09/25
Period Open: 1.8300
1.9200 -38.02%
on 01/22/25
-0.6400 (-34.97%)
since 01/16/25
52-Week
0.9200 +29.35%
on 04/09/25
Period Open: 9.2000
22.5000 -94.71%
on 09/17/24
-8.0100 (-87.07%)
since 04/16/24

Most Recent Stories

More News
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs GlobeNewswire - Thu Jan 9, 12:00PM CST

IGMS : 1.1900 (-6.30%)
Snowflake Stock Jumps Over 21% In Premarket Following Beat-and-Raise Q3: Retail Brace For ‘Parabolic’ Run Stocktwits - Thu Nov 21, 2024

Snowflake CEO Sridhar Ramaswamy said, “Our obsessive drive to produce product cohesion and ease of use has built Snowflake into the easiest and most cost effective enterprise data platform.”

SNOW : 146.08 (-0.31%)
IGMS : 1.1900 (-6.30%)
IWL : 129.33 (-2.33%)
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire - Fri Nov 8, 2024

IGMS : 1.1900 (-6.30%)
IGM Biosciences to Present at Three Upcoming Investor Conferences GlobeNewswire - Mon Nov 4, 2024

IGMS : 1.1900 (-6.30%)
Wall Street - Trader at NYSE by Orhan Akkurt via Shutterstock
Stock Index Futures Mixed Ahead of U.S. JOLTs Report and Fed Speak, Nike Earnings on Tap Barchart - Tue Oct 1, 2024

December S&P 500 E-Mini futures (ESZ24) are down -0.13%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.06% this morning as investors awaited the latest reading on U.S. job openings, comments...

CVS : 68.55 (-0.54%)
AAPL : 194.27 (-3.89%)
MKC : 73.54 (-2.30%)
IGMS : 1.1900 (-6.30%)
F : 9.40 (-0.53%)
NQZ24 : 20,947.98s (-0.78%)
MU : 69.33 (-2.41%)
HPQ : 23.47 (-1.14%)
NKE : 53.55 (-2.33%)
1COV.D.DX : 58.460 (+0.05%)
PAYX : 145.57 (-1.39%)
UPS : 94.20 (-2.38%)
Change in Medivir's Board of Directors PR Newswire - Fri Oct 20, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

IGMS : 1.1900 (-6.30%)
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles PR Newswire - Thu Oct 5, 2023

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Pareto Securities Healthcare Conference PR Newswire - Thu Sep 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

IGMS : 1.1900 (-6.30%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's patent application for fostrox approved in China PR Newswire - Mon Jun 19, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Redeye Growth Day PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Change in the number of shares and votes in Medivir AB (publ) PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May...

IGMS : 1.1900 (-6.30%)
Medivir to present at the ABGSC Life Science Summit PR Newswire - Tue May 30, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima PR Newswire - Mon Sep 4, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC PR Newswire - Fri Sep 1, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Erik Penser Bank Company Event PR Newswire - Wed Aug 23, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council PR Newswire - Mon Aug 7, 2023

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 1.1900 (-6.30%)
Medivir's patent application for fostrox approved in China PR Newswire - Mon Jun 19, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima PR Newswire - Fri Jun 2, 2023

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Medivir to present at the Redeye Growth Day PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
Change in the number of shares and votes in Medivir AB (publ) PR Newswire - Wed May 31, 2023

/PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May...

IGMS : 1.1900 (-6.30%)
Medivir to present at the ABGSC Life Science Summit PR Newswire - Tue May 30, 2023

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 1.1900 (-6.30%)
More news for this symbol

Business Summary

IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences...

See More

IGMS Related ETFs

Managed Assets
Percent
Symbol %Holdings 3M %Chg
IGMS -34.97%
Igm Biosciences Inc
VTI 0% -12.02%
Total Stock Market ETF Vanguard
VTWO 0% -17.72%
Russell 2000 Vanguard
VXF 0% -18.09%
Extended Market Index ETF Vanguard
VHT 0% -5.00%
Healthcare ETF Vanguard
SCHA 0% -18.05%
Schwab U.S. Smallcap ETF
Symbol %Holdings 3M %Chg
IGMS -34.97%
Igm Biosciences Inc
QQQS 0.08% -26.95%
Invesco Nasdaq Future Gen 200 ETF
IWC 0.01% -20.09%
Micro-Cap Ishares ETF
VTWG 0.01% -18.67%
Russell 2000 Growth Vanguard
VTWO 0% -17.72%
Russell 2000 Vanguard
VXF 0% -18.09%
Extended Market Index ETF Vanguard

IGMS Related stocks

Symbol Last 3M %Chg
IGMS 1.1900 -34.97%
Igm Biosciences Inc
AZN 67.05 +0.21%
Astrazeneca Plc ADR
AMGN 282.64 +4.90%
Amgen Inc
GILD 104.88 +14.44%
Gilead Sciences Inc
VRTX 485.89 +16.53%
Vertex Pharmaceutic
BMY 49.36 -12.45%
Bristol-Myers Squibb Company

Compare Symbols

Key Turning Points

Daily
52-Week
3rd Resistance Point 1.3803
2nd Resistance Point 1.3303
1st Resistance Point 1.2601
Last Price 1.1900
1st Support Level 1.1399
2nd Support Level 1.0899
3rd Support Level 1.0197

See More

52-Week High 22.5000
Fibonacci 61.8% 14.2564
Fibonacci 50% 11.7100
Fibonacci 38.2% 9.1636
Last Price 1.1900
52-Week Low 0.9200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro
Wed, Apr 23, 2025 5:00 PM UTC
Reserve Your Spot